Radiogenomics in prostate cancer evaluation. Issue 4 (July 2021)

• Record Type: Journal Article
• Authors: Thenault, Ronan; Gasmi, Anis; Khene, Zine-Edine; Bensalah, Karim; Mathieu, Romain
• Is Part Of: Current opinion in urology. Volume 31:Issue 4(2021)
• Publication Date: 2021-07
• Subjects: artificial intelligence -- deep learning -- genomics -- prostate cancer -- radiogenomics -- radiomics -- urology; Urology -- Periodicals; Review Literature -- Bibliography; Review Literature -- Periodicals; Male Urogenital Diseases -- Bibliography; Male Urogenital Diseases -- Periodicals; Female Urogenital Diseases -- Bibliography; Female Urogenital Diseases -- Periodicals; Urologic Diseases -- Bibliography; Urologic Diseases -- Periodicals; Periodicals; 616.6005
• DOI: 10.1097/MOU.0000000000000902
• Languages: English
• ISSNs: 1473-6586

Abstract

Abstract : Purpose of review: Radiogenomics, fusion between radiomics and genomics, represents a new field of research to improve cancer comprehension and evaluation. In this review, we give an overview of radiogenomics and its most recent and relevant applications in prostate cancer management. Recent findings: Literature about radiogenomics in prostate cancer emerged last 5 years but remains scarce. Radiogenomics in prostate cancer mainly rely on MRI-based features. Several imaging biomarkers, mostly based on the identification of radiomic features from deep learning studies, have been studied for the prediction of genomic profiles, such as PTEN Decipher Oncotype DX or Prolaris expression. However, despite promising results, several limitations still preclude any integration of radiogenomics in daily practice. Summary: In the future, the emergence of artificial intelligence in urology, with an increasing use of radiomics and genomics data, may enable radiogenomics to assume a growing role in the evaluation of prostate cancer, with a noninvasive and personal approach in the field of personalized medicine. Further efforts are necessary for integration of this promising approach in prostate cancer decision-making.